Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

Cost-effectiveness of vaccination against pneumococcal infection of adults at risk within the federal and regional programs

The aim. of the work was to evaluate the cost-effectiveness of vaccination with the 13-vaIent pneumococcal conjugate vaccine (PCV13) and its combination with the 23-valent pneumococcal polysaccharide vaccine (PPV23) of immunocompetent adult patients with different levels of risk of pneumococcal infe...

Full description

Bibliographic Details
Main Authors:	A. V. Rudakova, N. I. Briko, Yu. V. Lobzin, L. S. Namazova-Baranova, O. M. Drapkina, S. N. Avdeev, L. Yu. Drozdova, G. L. Ignatova, I. S. Koroleva, V. A. Korshunov, M. P. Kostinov
Format:	Article
Language:	Russian
Published:	Journal Infectology 2019-12-01
Series:	Журнал инфектологии
Subjects:	pneumonia vaccinal prevention adults pneumococcal conjugated vaccine cost-effectiveness
Online Access:	https://journal.niidi.ru/jofin/article/view/956

Similar Items

VACCINATION AGAINST PNEUMOCOCCAL INFECTIONS IN RUSSIAN FEDERATION: SOCIAL AND PHARMACOECONOMIC ASPECTS
by: A. V. Rudakova, et al.
Published: (2018-10-01)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014-01-01)

Vaccine Prevention of Pneumococcal Infection in Children
by: Alexander A. Baranov, et al.
Published: (2018-07-01)

Vaccinal Prevention of Pneumococcal Infection in Children
by: A. A. Baranov, et al.
Published: (2015-12-01)

A Decade of Experience in the use of 13-Valent Conjugated Polysaccharide Pneumococcal Vaccine in Russian Federation
by: N. I. Briko, et al.
Published: (2023-09-01)

Cost-Effectiveness of Pneumococcal Vaccination among Patients with Diabetes Mellitus
by: A. V. Rudakova, et al.
Published: (2022-11-01)

Vaccinal Prevention of Lower Respiratory Tract Pneumococcal Disease in Adults Without Immunosuppression
by: I. A. Guchev
Published: (2020-05-01)

Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01)

Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation
by: V. A. Korshunov, et al.
Published: (2025-01-01)

Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States
by: Andrew D. Wiese, et al.
Published: (2019-04-01)

Evaluating clinical effectiveness and impact of anti-pneumococcal vaccination in adults after universal childhood PCV13 implementation in Catalonia, 2017–2018
by: Angel Vila-Córcoles, et al.
Published: (2023-04-01)

Vaccination against Pneumococcal Infections of High-Risk People: Pharmacoeconomic Aspects
by: A. V. Rudakova, et al.
Published: (2020-01-01)

Strategies for pneumococcal vaccination in older adults in the coming era
by: Kei Nakashima, et al.
Published: (2024-12-01)

The Results of a Three-Year Pneumococcal Vaccination of Children in Russia
by: Nikolay I. Briko, et al.
Published: (2018-10-01)

Routine infant vaccination of pneumococcal conjugate vaccines has decreased pneumonia across all age groups in Northern Spain
by: I. Rivero-Calle, et al.
Published: (2020-06-01)

The effectiveness of immunization of children against Pneumococcal infection in Penza, Russia
by: O. N. Lesina, et al.
Published: (2019-04-01)

Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
by: Cornelis H. van Werkhoven
Published: (2017-05-01)

The Analysis of Scientific Data on the Efficacy of Pneumococcal Conjugated Vaccine in the Cohort of Children with Bronchial Asthma
by: Tatiana A. Kaliuzhnaia, et al.
Published: (2020-11-01)

The potential role of pneumococcal conjugate vaccine in reducing acute respiratory inflammation in community-acquired pneumococcal pneumonia
by: Ching-Fen Shen, et al.
Published: (2020-08-01)

Review of global use of licensed vaccines and development of new vaccines for the prevention of pneumococcal infection
by: M. V. Savkina, et al.
Published: (2021-12-01)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021-03-01)

Immunological and Epidemiological Aspects of the Immunogenicity of Streptococcus Pneumoniae Serotype 3 Capsular Polysaccharide in Pneumococcal Vaccines
by: A. E. Zaitsev, et al.
Published: (2020-04-01)

Effect of different schedules of ten-valent pneumococcal conjugate vaccine on pneumococcal carriage in Vietnamese infants: results from a randomised controlled trialResearch in context
by: Heidi Smith-Vaughan, et al.
Published: (2023-03-01)

Impact of the 10-valent pneumococcal conjugate vaccine on the incidence of respiratory and ENT diseases and antibiotic consumption in children under 5 years of age in Barnaul
by: Kozyanova Yu.A., et al.
Published: (2018-05-01)

Childhood invasive pneumococcal disease caused by non-7-valent pneumococcal vaccine (PCV7) serotypes under partial immunization in Taiwan
by: Ching-Fen Shen, et al.
Published: (2013-09-01)

NEXT GENERATION PNEUMOCOCCAL CONJUGATE VACCINES EFFICACY AND EFFECTIVENESS IN DIFFERENT REGIONS OF THE WORLD
by: O. P. Kovtun, et al.
Published: (2014-01-01)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012-02-01)

Serotype distribution of Streptococcus pneumoniae and potential impact of pneumococcal conjugate vaccines in China: A systematic review and meta-analysis
by: Kaile Chen, et al.
Published: (2018-06-01)

Pharmacoeconomic aspects of vaccination against Pneumococcal Infection in Russia
by: A. V. Rudakova, et al.
Published: (2014-09-01)

Seven-Valent Pneumococcal Conjugate Vaccine and Nasopharyngeal Microbiota in Healthy Children
by: Giske Biesbroek, et al.
Published: (2014-02-01)

CLINICAL AND EPIDEMIOLOGICAL ASSESSMENT OF THE EFFECTIVENESS OF VACCINATION OF CHILDREN AGAINST PNEUMOCOCCAL INFECTION IN THE AMUR REGION
by: A. G. Chuchalin, et al.
Published: (2016-06-01)

Impact of vaccination with pneumococcal vaccines on recurrent pneumonia in patients with chronic obstructive pulmonary disease
by: Galina L. Ignatova, et al.
Published: (2022-12-01)

Radiographically confirmed community-acquired pneumonia in hospitalized adults due to pneumococcal vaccine serotypes in Sweden, 2016–2018—The ECAPS study
by: Karin Hansen, et al.
Published: (2023-02-01)

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan
by: Ching-Fen Shen, et al.
Published: (2021-09-01)

Evolution of pneumococcal infections in adult patients during a four-year period after vaccination of a pediatric population with 13-valent pneumococcal conjugate vaccine
by: Antoni Payeras, et al.
Published: (2015-04-01)

The remaining challenges of pneumococcal disease in adults
by: E. Ludwig, et al.
Published: (2012-03-01)

Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England
by: Salini Mohanty, et al.
Published: (2023-01-01)

Incidence of pneumococcal disease in children in Germany, 2014–2019: a retrospective cohort study
by: Jessica Weaver, et al.
Published: (2024-11-01)

Rationale and methods of a randomized controlled trial of immunogenicity, safety and impact on carriage of pneumococcal conjugate and polysaccharide vaccines in infants in Papua New Guinea
by: Deborah Lehmann, et al.
Published: (2017-12-01)

Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
by: Matthew Wasserman, et al.
Published: (2019-03-01)